|Dr. Pankaj Modi||Chief Science Officer, CEO & Director||N/A||N/A||1955|
|Mr. Dean Hanisch||VP of Bus. Devel. & Director||N/A||N/A||1970|
|Mr. W. Campbell Birge B.A., BED, M.Sc.||Pres & Director||N/A||N/A||1953|
|Mr. Robert Allen C.A.||Chief Financial Officer||N/A||N/A||N/A|
|Mr. Marc Lakmaaker||Special Advisor & Sr. VP of Commercial Devel.||N/A||N/A||N/A|
CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment. It focuses on fast dissolving drug delivery systems. The company's technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or synthetic cannabis extracts to deliver treatment as an alternate to smoking and ingestion. Its principal asset is a patented orally administered wafer, an orally administrable wafer comprising at least one physiologically acceptable film forming agent. The company was formerly known as Mindesta Inc. and changed its name to CTT Pharmaceutical Holdings, Inc. in July 2015. The company is based in Ottawa, Canada.
CTT Pharmaceutical Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.